Near‐infrared photoimmunotherapy targeting PD‐L1 : Improved efficacy by preconditioning the tumor microenvironment
Cancer Science · 2024-07 · 115 (7) · 2396-2409
DOI: 10.1111/cas.16195 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 26.04.2024. Verfasst von Fuyuki F Inagaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Tumor Microenvironment, B7-H1 Antigen, Immunotherapy, Phototherapy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intramural NIH HHS, National Center for Global Health and Medicine, NCI NIH HHS.
Abstract (Originalsprache)
Near‐infrared photoimmunotherapy (NIR‐PIT) is a new type of cancer therapy that employs antibody‐IRDye700DX conjugates (AbPCs) and near‐infrared (NIR) light at a wavelength of 689 nm, the excitation wavelength of IR700. Administered intravenously, injected AbPCs bind specifically to cells expressing the target antigen, whereupon NIR light exposure causes rapid, selective killing. This process induces an anticancer T cell response, leading to sustained anticancer host immune response. Programmed cell death ligand‐1 (PD‐L1) is a major inhibitory immune checkpoint molecule expressed in various cancers. In this study, we first assessed the efficacy of PD‐L1‐targeted NIR‐PIT (αPD‐L1‐PIT) in immune‐competent tumor mouse models. αPD‐L1‐PIT showed a significant therapeutic effect on the tumor models with high PD‐L1 expression. Furthermore, αPD‐L1‐PIT induced an abscopal effect on distant tumors and long‐term immunological memory. In contrast, αPD‐L1‐PIT was not as effective for tumor models with low PD‐L1 expression. To improve the efficacy of PD‐L1‐targeted NIR‐PIT, PEGylated interferon‐gamma (IFNγ) was administered with αPD‐L1‐PIT. The combination therapy improved the treatment efficacy by increasing PD‐L1 expression leading to more efficient cell killing by αPD‐L1‐PIT. Furthermore, the PEGylated IFNγ led to a CD8+ T cell‐dominant tumor microenvironment (TME) with an enhanced anticancer T cell response after αPD‐L1‐PIT. As a result, even so‐called cold tumors exhibited complete responses after αPD‐L1‐PIT. Thus, combination therapy of PEGylated IFNγ and PD‐L1‐targeted NIR‐PIT has the potential to be an important future strategy for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Fuyuki F Inagaki, Aki Furusawa, Ryuhei Okada, Hisataka Kobayashi
Förderung
- Intramural NIH HHS
- National Center for Global Health and Medicine
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Inagaki, F. F., Kano, M., Furusawa, A., Kato, T., Okada, R., Fukushima, H., Takao, S., Okuyama, S., Choyke, P. L., & Kobayashi, H. (2024). Near‐infrared photoimmunotherapy targeting PD‐L1 : Improved efficacy by preconditioning the tumor microenvironment. Cancer Science, 115(7), 2396-2409. https://doi.org/10.1111/cas.16195
Vancouver
Inagaki FF, Kano M, Furusawa A, Kato T, Okada R, Fukushima H, et al. Near‐infrared photoimmunotherapy targeting PD‐L1 : Improved efficacy by preconditioning the tumor microenvironment. Cancer Science. 2024;115(7):2396-2409. doi:10.1111/cas.16195
BibTeX
@article{Inagaki2024,
author = {Inagaki, Fuyuki F and Kano, Makoto and Furusawa, Aki and Kato, Takuya and Okada, Ryuhei and Fukushima, Hiroshi and Takao, Seiichiro and Okuyama, Shuhei and Choyke, Peter L and Kobayashi, Hisataka},
title = {Near‐infrared photoimmunotherapy targeting PD‐L1 : Improved efficacy by preconditioning the tumor microenvironment},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {7},
pages = {2396--2409},
doi = {10.1111/cas.16195}
}
EUVIMED